New Three-Drug cocktail aims to tackle Hard-to-Treat myeloma
NCT ID NCT05560399
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a combination of three drugs—iberdomide (a pill), elotuzumab (given by IV), and dexamethasone—in people whose multiple myeloma has returned or stopped responding to prior treatments. The study is small (up to 37 people) and primarily looks at safety and the best dose, while also checking if the cancer shrinks. It is too early to know if this combo will become a standard therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iberdomide (oral pill) combined with elotuzumab (IV) and dexamethasone (oral or IV)
What this could lead to
If it works, this could offer a new treatment option for people with multiple myeloma that has come back or stopped responding to other therapies.
What could go wrong
This is a very early, small study (only 7 participants so far) focused on safety and dosing. It may not show strong benefit, and side effects could limit its use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine
New York, New York, 10029, United States